Clinical and Genetic Characterization of Individuals With Achromatopsia

Beacon Therapeutics56 enrolled

Overview

The purpose of this study is to identify individuals with achromatopsia caused by mutations in the CNGB3 gene and characterize their clinical condition using several tests of visual function every 6 months for up to 1.5 years.

Individuals with a clinical diagnosis of achromatopsia will be asked to provide informed consent and will then have a single 5 mL blood sample drawn for DNA sequence analysis of genes known to cause achromatopsia, including the CNGB3 gene. All participants will be informed of the results of testing for these mutations. Those with mutations in both alleles of the CNGB3 gene will be evaluated every 6 months for up to 1.5 years by using a variety of non-invasive visual function tests to more fully characterize their clinical condition. This testing will include routine ophthalmic examination and tests of visual acuity, color vision, reading speed, perimetry, nystagmus, light sensitivity, optical coherence tomography, adaptive optics retinal imaging, electroretinography, fundus photography and completion of a quality of life questionnaire.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Achromatopsia

Eligibility

Sex: ALLMin age: 6 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Clinical diagnosis of achromatopsia (screening portion of study); 2. Molecular confirmation of mutations in the CNGB3 gene (main portion of study); 3. At least 6 years of age; 4. Willing and able to perform study procedures; 5. Signed informed consent(s) obtained (and child assent where applicable). Exclusion Criteria: 1. Not able to have a blood sample drawn; 2. Pre-existing eye conditions that would interfere with interpretation of study endpoints (e.g. glaucoma, corneal or lenticular opacities, diabetic retinopathy, history of retinal detachment); 3. Participating in an interventional research study of drugs or devices for treatment of achromatopsia or other retinal diseases; 4. Use of medications that may impair color vision (e.g. hydroxychloroquine); 5. Any condition which leads the investigator to believe that the participant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for participation.

Locations (5)

VitreoRetinal Associates

Gainesville, Florida, United States

Bascom Palmer Eye Institute

Miami, Florida, United States

Pangere Center for Inherited Retinal Diseases, The Chicago Lighthouse for People Who Are Blind or Visually Imp

Chicago, Illinois, United States

Casey Eye Institute, Oregon Health & Science University

Portland, Oregon, United States

Outcomes

Primary Outcomes

Visual acuity

Visual acuity will be measured by EVA or ETDRS methods

Time frame: Annually for up to 1.5 years

Secondary Outcomes

Color Vision

Color vision will be measured by Farnsworth D-15 test and anomaloscope

Time frame: annually for up to 1.5 years

Adaptive Optics Retinal Imaging

Adaptive optics retinal imaging will be performed using the method of Genead et al. (Invest Ophthalmol Vis Sci 2011;52:7298-308).

Time frame: annually for up to 1.5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.